[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"age-related-dry-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:age-related-dry-macular-degeneration":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,47],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":4},"100658062","mind-amd-study-a-multidisciplinary-investigation-of-neuroretinal-damage-in-age-related-macular-degeneration-100658062",false,"NCT07847151","MIND-AMD Study: a Multidisciplinary Investigation of Neuroretinal Damage in Age-related Macular Degeneration.","MIND-AMD","Inclusion Criteria:\n\n* Confirmed diagnosis of AMD\n\nExclusion Criteria:\n\n* low BCVA (\\\u003C20\u002F100)\n* other ocular diseases\n* uncontrolled systemic diseases potentially affecting data interpretation",true,"ALL","50 Years",{"count":20,"type":21},160,"ESTIMATED","OBSERVATIONAL","Age-related macular degeneration (AMD) is the major cause of legal blindness in developed countries. Intermediate AMD represents the most frequent stage. However, it often evolves towards complicated stages, namely neovascular AMD or geographic atrophy (GA). Despite the available treatments, the visual outcome is highly heterogeneous. The scientific interest is growing regarding the assessment of neuroretinal changes in AMD. Although AMD is mainly considered an outer retinal disease, recent evidence suggests a major involvement of retinal glia and neurons, i.e. an involvement of the inner retina. This damage may remarkably affect the morphological and functional AMD outcome, subverting retinal signal transmission cascade and more clearly explaining the outcome of the disease. The main goal of this study is to perform a multidisciplinary, multicenter, both prospective and retrospective evaluation of neuroretinal degeneration in different AMD stages in preclinical and clinical models.",[25,26,27,28,29],"Age-Related (Dry) Macular Degeneration","Age-Related Macular Degeneration (AMD)","AMD Population - Intermediate or Advanced AMD","AMD and Macular Edema","Neovascular (Wet) Age-Related Macular Degeneration",[31,32,33,34],"Age-related macular degeneration","Multimodal retinal imaging","Mouse model","microRNA","NOT_YET_RECRUITING","2026-09-22",{"date":38,"type":39},"2026-09-29","ACTUAL",{"date":41,"type":21},"2027-01-02",{"date":43,"type":21},"2030-01-02",{"name":45,"class":46},"IRCCS San Raffaele","OTHER",{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":17,"minAge":54,"maxAge":4,"enrollmentInfo":55,"targetDuration":57,"studyType":22,"phases":4,"briefSummary":58,"conditions":59,"keywords":60,"overallStatus":64,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":75},"100627280","real-world-evaluation-of-ai-enabled-multi-spectral-imaging-msi-for-amd-biomarker-detection-100627280","NCT07446582","Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection","Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) at Point-of-Care to Identify and Quantify Biomarkers of Non-Exudative Age-Related Macular Degeneration","Inclusion Criteria: AMD subjects:\n\n1. Subjects over 40 years of age diagnosed for ne AMD\n2. Subject must be able to understand and must sign an IRB-approved ICF\n3. Subject must have minimum of one prior visit to the clinic\n4. Prior imaging must show signs of neAMD (e.g. drusen of different sizes and types with macular pigmentary changes, complete or incomplete retinal pigment epithelium and outer retinal atrophy) at least in one eye\n\nHealthy subjects:\n\n1. Subjects over 40 years of age have not been diagnosed with any type of AMD and prior imaging that shows no signs of AMD or other types of retinopathies.\n2. A minimum of light perception visual acuity is required to detect the fixation target during imaging.\n3. Two masked clinicians must confirm and categorize them into healthy eyes. -\n\nExclusion Criteria:\n\n* Assessed prior to any considerations of inclusion:\n\n  1. Eyes with significant refractive media opacity (e.g. corneal opacity, significant cataract) that prevents adequate imaging\n  2. Severe Refractive Error: Extreme high myopia (≥ -10.00D) or hyperopia (≥ +6.00D) that may compromise image quality.\n  3. Unstable Ocular Conditions: Active ocular infections, severe uveitis, or status-post ocular trauma\n  4. Recent Intraocular Surgery: Patients who have undergone intraocular surgery (e.g., cataract, retinal, or glaucoma surgery) within the past 3 months (except for intravitreal injections for GA therapy).\n  5. History or Current Evidence of other types of retinopathy other than neAMD, e.g. Acute Retinal artery or Vein Occlusion, Diabetic Retinopathy, Idiopathic Epiretinal membrane, Myopic Maculopathy, Hypertension Retinopathy etc.\n  6. History of Vitrectomy or Scleral Buckling for any kind of Vitreoretinopathy, e.g. Retinal Detachment, Epiretinal Membrane, Proliferative Diabetic Retinopathy etc. that could distort imaging results.\n  7. Inability to Maintain Fixation: Including patients with advanced nystagmus, severe amblyopia, or cognitive impairments (dementia) affecting fixation stability.\n  8. Severe Dry Eye or Ocular Surface Disease: Conditions that may interfere with imaging quality or patient comfort during the procedure.\n  9. Subjects with essential tremor (head and neck tremors or unstable fixation to prevent adequate imaging)\n  10. Inability to understand and refusal to sign informed consent","40 Years",{"count":56,"type":21},1000,"1 Day","The goal of this observational clinical study is to learn if DeepMSI AI detects age-related macular degeneration (AMD) biomarkers with sensitivity and specificity equivalent to experienced clinicians in adults over 40 years old. The main questions it aims to answer are:\n\n* Does DeepMSI AI detect AMD biomarkers with sensitivity equivalent to experienced clinicians?\n* Does DeepMSI AI detect AMD biomarkers with specificity equivalent to experienced clinicians? Participants' eyes will be imaged by MSI-120 and their images will be analyzed for AMD biomarkers by both DeepMSI AI and retina specialists independently.\n\nResearchers will compare retina image analysis from DeepMSI AI with ground truth (clinicians' interpretations) to see if AI achieves equivalency in sensitivity and specificity.",[25],[61,62,63],"Age-Related Macular Degeneration","AI","Multispectral imaging","RECRUITING","2026-03-09",{"date":67,"type":39},"2026-03-11",{"date":69,"type":39},"2026-02-01",{"date":71,"type":21},"2026-09-05",{"name":73,"class":74},"AI-Spectral","INDUSTRY",1]